Alzheimer disease in the United States (2010–2050) estimated using the 2010 census

By L. Hebert, J. Weuve, P. Scherr, Denis A. Evans. Neurology, 2013

2,503 citations recorded by the source corpus.

Subfields: Molecular Biology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/e3766b6523df9c97ae3171f366943254334bc418

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Lin F. Yang
2. A. Barnett

In Physiology

1. Liara Rizzi
2. Matheus Roriz‐Cruz
3. Brian J. Hall
4. Ester Cerin
5. Idiane Rosset

In Psychiatry and Mental health

1. Liara Rizzi
2. Matheus Roriz‐Cruz
3. Idiane Rosset

Citations in the corpus

• Clinical epidemiology of Alzheimer’s disease: assessing sex and gender differences (2014, neutral): “Recent estimates suggest that almost two-thirds of the individuals diagnosed with AD are women.(3) A reason”
• Global Epidemiology of Dementia: Alzheimer's and Vascular Types (2014, background): “2 million old Americans have Alzheimer’s disease, that is, one in nine individuals aged 65 years or older (11%) [28], and themajority are women, probably because women generally live longer thanmen.”
• Racial and ethnic estimates of Alzheimer’s disease and related dementias in the United States (2015–2060) in adults aged ≥65 years (2018, background): “Although the gold standard for obtaining reliable estimates of the prevalence of dementia would be to clinically evaluate a nationally representative sample of older Americans [12], such studies can be prohibitively expensive, and it is unclear whether the geographically restricted cohort used to es”
• Inflammation as a central mechanism in Alzheimer's disease (2018, background): “[2] Hebert LE, Weuve J, Scherr PA, Evans DA.”
• 2020 Alzheimer's disease facts and figures (2020, methodology): “org/trajectory: (1) cost data from the 2011 Medicare Current Beneficiary Survey (MCBS) were used rather than data from the 2008 MCBS; (2) prevalence among older adults was assumed to equal the prevalence levels from Hebert and colleagues62 and included in this report (5.8 million in 2019),A2 rather ”
• Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population‐based perspective (2015, neutral): “[11] Hebert LE, Weuve J, Scherr PA, Evans DA.”
• Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019 (2022, positive): “19 Other work has applied macrosimulation techniques, using estimates of incidence, progression, and mortality, although the data requirements to fit these models are large while the evidence base for such data is sparse.”
• 2016 Alzheimer's disease facts and figures (2016, neutral): “Created from data from Hebert and colleagues [33].”